Valneva’s inactivated COVID-19 vaccine candidate, VLA2001

To help fight the pandemic, specialty vaccine company Valneva has developed VLA2001. As of April 2021, it is the only inactivated vaccine candidate in clinical trials against COVID-19 in clinical development in Europe.


About the vaccine candidate VLA2001

  • Inactivated
  • Adjuvanted with Alum and CpG 1018
  • Highly-purified
  • Whole virus candidate
  • Vero-cell based
  • Using the manufacturing platform of Valneva’s commercial Japanese encephalitis (JE) vaccine
     

Phase 3 clinical trial for Valneva's COVID-19 vaccine candidate

The Phase 3 trial “Cov-Compare” was initiated in April 2021 and will compare VLA2001 against AstraZeneca’s conditionally approved vaccine, Vaxzevria, in a comparative immunogenicity trial including approximately 4,000 participants (press release).

Valneva reported positive Phase 1/2 trial data for VLA2001 at the beginning of April 2021 (press release). VLA2001 was well tolerated with no safety concerns identified. In the high dose group, IgG seroconversion rate was 100%, and neutralizing antibody titers were at or above levels generally seen in convalescent sera. Based on the data assessed, the Company has decided to advance the high dose into the Phase 3 clinical trial.

 

Agreement with the UK & discussions with the EC and other countries

In September 2020, Valneva announced a collaboration with the UK government, which has the option to purchase up to 190 million doses through 2025. So far, the UK Government has ordered 100 million doses to be delivered in 2021 and 2022 and retains options over a further 90 million doses for supply between 2023 and 2025. The UK government is also investing up-front in the scale up and development of the vaccine candidate.

In January 2021, Valneva announced it is in advanced discussions with the European Commission (EC) for the supply of up to 60 million doses of VLA2001. In April 2021, Valneva announced it is now focusing on bilateral discussions, on a country by country basis, to supply VLA2001 and is consequently deprioritizing the ongoing centralized discussions with the European Commission (EC).

Read more about VLA2001 here: https://valneva.com/research-development/covid-19-vla2001/